Cardiac toxicity in breast cancer patients: From a fractional point of view to a global assessment

Cancer Treatment Reviews

Volumn 37, Issue 4, 2011, Pages 321-330

  Chargari, Cyrus ^a   Kirov, Krassen M ^b   Bollet, Marc A ^b   Magné, Nicolas ^c   Védrine, Lionel ^a   Cremades, Serge ^d   Beuzeboc, Philippe ^b   Fourquet, Alain ^b   Kirova, Youlia M ^b  

^a University of Paris Descartes   (France)

^b INSTITUT CURIE   (France)

^c Institut de Cancerologie de la Loire   (France)

^d SERVICE D ENDOCRINOLOGIE   (France)

Author keywords

Breast cancer; Cardiac toxicity; Chemotherapy; Radiation therapy; Trastuzumab

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; BEVACIZUMAB; BUPIVACAINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DESFLURANE; DOCETAXEL; DOXORUBICIN; ERYTHROPOIETIN; FLUOROURACIL; HALOTHANE; ISOFLURANE; LAPATINIB; LETROZOLE; PACLITAXEL; PROPOFOL; RECOMBINANT ERYTHROPOIETIN; SEVOFLURANE; SORAFENIB; SUNITINIB; TAMOXIFEN; THIOPENTAL; TRASTUZUMAB;

AGE; ANEMIA; ANGINA PECTORIS; BODY MASS; BREAST CANCER; CANCER RADIOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CEREBROVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; DRUG EFFECT; DRUG SAFETY; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTENSITY MODULATED RADIATION THERAPY; MENOPAUSE; QT PROLONGATION; RADIATION DOSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; STRESS; SYSTOLIC DYSFUNCTION; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HEART DISEASES; HUMANS; INCIDENCE; RISK ASSESSMENT; RISK FACTORS; WORLD HEALTH;

EID: 79953083995     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.08.007     Document Type: Review

References (111)

1. Giordano S.H., Kuo Y.F., Freeman J.L., Buchholz T.A., Hortobagyi G.N., Goodwin J.S. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 2005, 97:419-424.
2. Magné N, Chargari C, MacDermed D, Védrine L, Spano JP, Khayat D. Tomorrow's targeted therapies in breast cancer patients: a potential for increased radiation-induced cardiac toxicity. Crit Rev Oncol Haematol, in press [PMID: 20138541].
3. Magné N., Védrine L., Chargari C. Impact on cardiac toxicity with trastuzumab and radiotherapy? The question is still ongoing. J Clin Oncol 2009, 27:239.
4. Clarke M., Collins R., Darby S., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 366:2087-2106.
5. Hooning M.J., Aleman B.M., van Rosmalen A.J.M., et al. Cause-specific mortality in long term survivors of breast cancer: a 25-year follow-up study. Int J Radiat Oncol Biol Phys 2006, 64:1081-1091.
6. Gyenes G., Rutqvist L.E., Liedberg A., et al. Long-term cardiac mortality in a randomized trial of pre- and post-operation radiation therapy versus surgery alone in primary breast cancer. Radiother Oncol 1998, 48:185-190.
7. Paszat L.F., Mackillop W.J., Groome P.A., et al. Mortality from myocardial infarction following postlumpectomy radiotherapy for breast cancer: a population-based study in Ontario, Canada. Int J Radiat Oncol Biol Phys 1999, 43:755-762.
8. Rutqvist L.E., Liedberg A., Hammar N., et al. Myocardial infarction among women with early-stage breast cancer treated with conservative surgery and breast irradiation. Int J Radiat Oncol Biol Phys 1998, 40:359-363.
9. Gagliardi G., Lax I., Söderström S., et al. Prediction of excess risk of long-term cardiac mortality after radiotherapy of stage I breast cancer. Radiother Oncol 1998, 46:63-71.
10. Højris I., Overgaard M., Christensen J.J., et al. Morbidity and mortality of ischemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomized trials. Lancet 1999, 354:1425-1430.
11. Rutqvist L.E., Johansson H. Mortality by laterality of the primary tumor among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer 1990, 61:866-868.
12. Roychoudhuri R., Robinson D., Putcha V., et al. Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study. BMC Cancer 2007, 15:7-9.
13. Clarke M., Collins R., Darby S., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 366:2087-2106.
14. Demirci S., Nam J., Hubbs J.L., Nguyen T., Marks L.B. Radiation-induced cardiac toxicity after therapy for breast cancer: interaction between treatment era and follow-up duration. Int J Radiat Oncol Biol Phys 2009, 73:980-987.
15. Vallis K.A., Pintilie M., Chong N., Holowaty E., Douglas P.S., Kirkbride P., et al. Assessment of coronary heart disease morbidity and mortality after radiation therapy for early breast cancer. J Clin Oncol 2002, 20:1036-1042.
16. Harris E.E.R. Cardiac mortality and morbidity after breast cancer treatment. Cancer Control 2008, 15:120-129.
17. Darby S.C., McGale P., Taylor C.W., Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 2005, 6:557-565.
18. Patt D.A., Goodwin J.S., Kuo Y.F., et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol 2005, 23:7475-7482.
19. Overgaard M., Hansen P.S., Overgaard J., et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish breast cancer cooperative group 82b trial. N Engl J Med 1997, 337:949-955.
20. Overgaard M., Jensen M.B., Overgaard J., et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish breast cancer cooperative group DBCG 82c randomised trial. Lancet 1999, 353:1641-1648.
21. Ragaz J., Jackson S.M., Le N., et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997, 337:956-962.
22. Lê M.G., Arriagada R., de Vathaire F., et al. Can internal mammary chain treatment decrease the risk of death for patients with medial breast cancers and positive axillary lymph nodes?. Cancer 1990, 66:2313-2318.
23. Chargari C., Castadot P., Macdermed D., Vandekerkhove C., Bourgois N., Van Houtte P., et al. Internal mammary lymph node irradiation contributes to heart dose in breast cancer. Med Dosim 2010, 35:163-168.
24. Romestaing P, Belot A, Hennequin C, Bosset J, Maingon P, Dubois J, et al. Ten-year results of a randomized trial of internal mammary chain irradiation after mastectomy. ASTRO 2009 [abst. 1].
25. Gagliardi G., Constine L.S., Moiseenki V., Correa C., Pierce L.J., Allen A.M., et al. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 2010, 76:77-85.
26. Castro Pena P., Kirova Y.M., Campana F., Dendale R., Bollet M.A., Fournier-Bidoz N., et al. Anatomical, clinical and radiological delineation of target volumes in breast cancer radiotherapy planning: individual variability, questions and answers. Br J Radiol 2009, 82:595-599.
27. Kirova Y.M., Servois V., Campana F., Dendale R., Bollet M.A., Laki F., et al. CT-scan based localization of the internal mammary chain and supra clavicular nodes for breast cancer radiation therapy planning. Radiother Oncol 2006, 79:310-315.
28. Taylor C.W., McGale P., Povall J.M., Thomas E., Kumar S., Dodwell D., et al. Estimating cardiac exposure from breast cancer radiotherapy in clinical practice. Int J Radiat Oncol Biol Phys 2009, 73:1061-1068.
29. Caudrelier J.M., Morgan S.C., Montgomery L., Lacelle M., Nyiri B., Macpherson M. Helical Tomotherapy for locoregional irradiation including the internal mammary chain in left-sided breast cancer: dosimetric evaluation. Radiother Oncol 2009, 90:99-105.
30. Gauer T., Engel K., Kiesel A., Albers D., Rade D. Comparison of electron IMRT to helical photon IMRT and conventional photon irradiation for treatment of breast and chest wall tumours. Radiother Oncol 2010, 94:313-318.
31. Coon AB, Dickler A, Kirk MC, et al. Tomotherapy and multifield intensity-modulated radiotherapy planning reduce cardiac doses in left-sided breast cancer patients with unfavorable cardiac anatomy. Int J Radiat Oncol Biol Phys, in press [PMID: 20004529].
32. Gianni L., Herman E.H., Lipshultz S.E., et al. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 2008, 22:3777-3784.
33. Takemura G., Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007, 49:330-352.
34. Fumoleau P., Roché H., Kerbrat P., et al. French adjuvant study group long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French adjuvant study group results. Ann Oncol 2006, 17:85-92.
35. Pinder M.C., Duan Z., Goodwin J.S., Hortobagyi G.N., Giordano S.H. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007, 25:3808-3815.
36. Von Hoff D.D., Layard M.W., Basa P., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979, 91:710-717.
37. Bonneterre J., Roché H., Kerbrat P., et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French adjuvant study group 05 randomized trial. J Clin Oncol 2005, 23:2686-2693.
38. Towns K., Bedard P.L., Verma S. Matters of the heart: cardiac toxicity of adjuvant systemic therapy for earlystage breast cancer. Curr Oncol 2008, 15:16-29.
39. van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2006; ncbi-n:CD005006.
40. Swain S.M., Whaley F.S., Gerber M.C., Ewer M.S., Bianchine J.R., Gams R.A. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997, 15:1333-1340.
41. Gianni L., Salvatorelli E., Minotti G. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovasc Toxicol 2007, 7:67-71.
42. Keefe D.L., Roistacher N., Pierri M.K. Clinical cardiotoxicity of 5-fluorouracil. J Clin Pharmacol 1993, 33:1060-1070.
43. Perez E.A., Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004, 22:322-329.
44. Francis P., Crown J., Di Leo A., et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: breast International Group 02-98 randomized trial. J Natl Cancer Inst 2008, 100:121-133.
45. Ewer M.S., Gibbs H.R., Swafford J., Benjamin R.S. Cardiotoxicity in patients receiving trastuzumab (herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?. Semin Oncol 1999, 26:96-101.
46. Seidman A., Hudis C., Pierri M.K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002, 20:1215-1221.
47. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
48. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
49. Suter T.M., Procter M., van Veldhuisen D.J., et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007, 25:3859-3865.
50. Liang K., Lu Y., Lin W., Ang K.K., Milas L., Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2003, 2:1113-1120.
51. Halyard M.Y., Pisansky T.M., Dueck A.C., et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG phase III trial N9831. J Clin Oncol 2009, 27:2638-2644.
52. Cameron D., Casey M., Press M., et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008, 112:533-543.
53. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
54. Perez E.A., Koehler M., Byrne J., Preston A.J., Rappold E., Ewer M.S. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008, 83:679-686.
55. Ewer M.S., Perez E.A., Baselga J., et al. Cardiac safety guidelines for the adjuvant use of trastuzumab (herceptin) in HER2-positive early breast cancer. Breast 2007, 16:63.
56. Moy B., Goss P.E. Lapatinib-associated toxicity and practical management recommendations. Oncologist 2007, 12:756-765.
57. Ramaswamy B., Shapiro C.L. Phase II trial of bevacizumab in combination with docetaxel in women with advanced breast cancer. Clin Breast Cancer 2003, 4:292-294.
58. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005, 23:792-799.
59. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
60. Mourad J.J., des Guetz G., Debbabi H., Levy B.I. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008, 19:927-934.
61. Scappaticci F.A., Skillings J.R., Holden S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007, 99:1232-1239.
62. Nalluri S.R., Chu D., Keresztes R., Zhu X., Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008, 300:2277-2285.
63. Burstein H.J., Elias A.D., Rugo H.S., et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008, 26:1810-1816.
64. Awada A, Hendlisz A, Whenham N et al. Phase I trial to evaluate safety, pharmacokinetics, and efficacy of sorafenib combined with docetaxel in patients with advanced, refractory solid tumors. Ann Oncol 2007;18:401 [abstr.].
65. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
66. Zhu X., Stergiopoulos K., Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009, 48:9-17.
67. Hutson T.E., Figlin R.A., Kuhn J.G., Motzer R.J. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008, 13:1084-1096.
68. Kannel W.B., Dawber T.R., Kagan A., Revotskie N., Stokes J. Factors of risk in the development of coronary heart disease-six-year follow-up experience: the Framingham study. Ann Intern Med 1961, 55:33-50.
69. Ridker P.M., Buring J.E., Rifai N., Cook N.R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA 2007, 297:611-619.
70. Clarke M. Meta-analyses of adjuvant therapies for women with early breast cancer: the early breast cancer trialists' collaborative group overview. Ann Oncol 2006, 17:59-62.
71. Hequet O., Le Q.H., Moullet I., et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004, 22:1864-1871.
72. Singal P.K., Li T., Kumar D., Danelisen I., Iliskovic N. Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem 2000, 207:77-86.
73. Mouridsen H., Keshaviah A., Coates A.S., et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol 2007, 25:5715-5722.
74. Matthews K.A., Meilahn E., Kuller L.H., Kelsey S.F., Caggiula A.W., Wing R.R. Menopause and risk factors for coronary heart disease. N Engl J Med 1989, 321:641-646.
75. Gierach G.L., Johnson B.D., Bairey Merz C.N., et al. Hypertension, menopause, and coronary artery disease risk in the Women's ischemia syndrome evaluation (WISE) study. J Am Coll Cardiol 2006, 47:50-58.
76. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998, 90:1371-1388.
77. Braithwaite R.S., Chlebowski R.T., Lau J., et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003, 18:937-947.
78. Buzdar A., Chlebowski R., Cuzick J., et al. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Curr Med Res Opin 2006, 22:1575-1585.
79. Forbes J.F., Cuzick J., Buzdar A., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9:45-53. ATAC trialists' group.
80. Chang J., Powles T.J., Ashley S.E., et al. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann Oncol 1996, 7:671-675.
81. Cattaneo M., Elisaf M.S., et al. Does tamoxifen enhance endothelial function by lowering the plasma levels of homocysteine? Effects of tamoxifen on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis effects of tamoxifen on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis response. Circulation 2001, 104:146-147.
82. Hozumi Y., Kawano M., Saito T., Miyata M. Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metabol 1998, 83:1633-1635.
83. Buzdar A., Howell A., Cuzick J., et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006, 7:633-643. ATAC trialists' group.
84. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005, 97:1262-1271.
85. Manson J.E., Hsia J., Johnson K.C., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003, 349:523-534.
86. Azria D., Belkacemi Y., Romieu G., et al. Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. Lancet Oncol 2010, 11:258-265.
87. Chargari C., Toillon R.A., Macdermed D., Castadot P., Magné N. Concurrent hormone and radiation therapy in patients with breast cancer: what is the rationale?. Lancet Oncol 2009, 10:53-60.
88. Hamed S., Barshack I., Luboshits G., Wexler D., Deutsch V., Keren G., et al. Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur Heart J 2006, 27:1876-1883.
89. Kim K.H., Oudit G.Y., Backx P.H. Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. J Pharmacol Exp Ther 2008, 324:160-169.
90. Frank H., Heusser K., Höffken B., Huber P., Schmieder R.E., Schobel H.P. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients. Kidney Int 2004, 66:832-840.
91. Aapro M., Leonard R.C., Barnadas A., et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the breast cancer-anemia and the value of erythropoietin (BRAVE) study. J Clin Oncol 2008, 26:592-598.
92. Aapro M., Osterwalder B., Scherhag A., Burger H.U. Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events. Br J Cancer 2009, 101:1961-1971.
93. Copeland S.E., Ladd L.A., Gu X.Q., Mather L.E. The effects of general anesthesia on the central nervous and cardiovascular system toxicity of local anesthetics. Anesth Analg 2008, 106:1429-1439.
94. Morrison S.G., Dominguez J.J., Frascarolo P., Reiz S. A comparison of the electrocardiographic cardiotoxic effects of racemic bupivacaine, levobupivacaine, and ropivacaine in anesthetized swine. Anesth Analg 2000, 90:1308-1314.
95. Weigt H.U., Kwok W.M., Rehmert G.C., Turner L.A., Bosnjak Z.J. Voltage-dependent effects of volatile anesthetics on cardiac sodium current. Anesth Analg 1997, 84:285-293.
96. Huettemann E., Junker T., Chatzinikolaou K.P., et al. The influence of anthracycline therapy on cardiac function during anesthesia. Anesth Analg 2004, 98:941-947.
97. Libert N, Tourtier JP, Védrine L, Chargari C. Vascular endothelial growth factor targeting: new hopes for oncologists, new challenges for anesthesiologists. Anesthesiology, in press [PMID: 20693871].
98. Ewer M.S., Lippman S.M. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005, 23:2900-2902.
99. Albini A., Pennesi G., Donatelli F., Cammarota R., De Flora S., Noonan D.M. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010, 102:14-25.
100. Ewer M.S., Lenihan D.J. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?. J Clin Oncol 2008, 26:1201-1203.
101. Bellenger N.G., Grothues F., Smith G.C., Pennell D.J. Quantification of right and left ventricular function by cardiovascular magnetic resonance. Herz 2000, 25:392-399.
102. Zethelius B., Berglund L., Sundström J., et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008, 358:2107-2116.
103. Perik P.J., De Vries E.G., Boomsma F., et al. Use of natriuric peptides for detecting cardiac dysfunction in long-term disease-free breast cancer survivors. Anticancer Res 2005, 25:3651-3657.
104. Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol, in press [PMID: 20679614].
105. Cawthon R.M., Smith K.R., O'Brien E., Sivatchenko A., Kerber R.A. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 2003, 361:393-395.
106. Tanner M., Isola J., Wiklund T., Erikstein B., Kellokumpu-Lehtinen P., et al. Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian breast group trial 9401. J Clin Oncol 2006, 24:2428-2436. Scandinavian breast group trial 9401.
107. Magné N, Castadot P, Chargari C, Di Leo A, Philippson C, Van Houtte P. Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients. Radiother Oncol 2009;90:116-2.
108. Magné N., Chargari C. Therapy Insight: anthracyclines and trastuzumab-the optimal management of cardiotoxic side effects. Nat Clin Pract Oncol 2008, 5:1.
109. Feenstra J., Grobbee D.E., Remme W.J., et al. Drug-induced heart failure. J Am Coll Cardiol 1999, 33:1152-1162.
110. Bird B.R., Swain S.M. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008, 14:14-24.
111. Lenihan D.J., Esteva F.J. Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer. Oncologist 2008, 13:1224-1234.